Gene Therapy Clinical Trials
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate cancers. Giving 18F-FSPG before a PET/CT scan may work better in helping researchers diagnose early lung cancer in patients with lung nodules.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: Computed Tomography
- drug: Fludeoxyglucose F-18
- drug: Fluorine F 18 L-glutamate Derivative BAY94-9392
- procedure: Positron Emission Tomography
Eligibility
Inclusion Criteria:
- Pulmonary nodule between the size of 7 to 30 mm. Subjects with multiple nodules may be
eligible if the dominant nodule is 7 to 30 mm
- Undergoing standard of care 18F-FDG PET imaging (for indeterminate pulmonary nodule)
- Current or former cigarette smoker, with >= 20 pack years
- Documented informed consent
Exclusion Criteria:
- History or previous diagnosis of lung cancer
- Cancer diagnosis within the last 5 years
- Pregnant or nursing
Ages Eligible for Study
45 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mahima Goel
650-723-0371
I'm interested